HAMILTON, BM / ACCESS Newswire / April 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and commercializing RNA delivery technology ...

Altamira Therapeutics (CYTOF) has delivered a -14.560% change over the past year, with a 52-week range between 0.050 and 0.148. What Is the Average Daily Trading Volume of Altamira Therapeutics (CYTOF ...

HAMILTON, BERMUDA / ACCESS Newswire / January 23, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and commercializing nucleic acid ...

Joseph Chen, left, and Kavitha Yaddanapudi, University of Louisville immuno-oncology researchers, using the CyTOF instrument for cancer immunotherapy research. Cancer remains one of the greatest ...

Altamira Therapeutics Ltd (CYTOF) is making significant progress in its RNA delivery business, focusing on nanoparticle formulation and process development. The company has successfully developed ...

HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery ...

Cell therapy has emerged as a transformative approach to treating a range of diseases, including cancers, autoimmune disorders and genetic conditions. It achieves this by harnessing living cells, such ...

Good day and welcome to the Altamira Therapeutics’ Full Year 2024 Financial Results and Business Update Call. Today’s conference is being recorded. I would now like to hand the conference over to your ...

Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery Circular mRNA significantly increasing protein expression vs. linear mRNA Filed provisional ...

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for ...